SCHEMBL2272066

SCHEMBL2272066

FC(F)(F)c1cc2cc[nH]c2cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK2A1 P68400 1/20 0.55
▸ GPR84 Q9NQS5 1/20 0.47
▸ AHR P35869 6/20 0.46
▸ NR4A2 P43354 2/20 0.46
▸ CMA1 P23946 1/20 0.46
▸ F7 P08709 1/20 0.46
▸ LTA4H P09960 1/20 0.46
▸ F3 P13726 1/20 0.46
▸ KIF11 P52732 1/20 0.44
▸ CTNNB1 P35222 1/20 0.39
▸ WNT3A P56704 1/20 0.39
▸ TRPV1 Q8NER1 3/20 0.39
▸ HSD17B10 Q99714 1/20 0.38
▸ NOTUM Q6P988 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37
▸ TYR P14679 1/20 0.37
▸ USP2 O75604 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ RAD51 Q06609 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22438351 0.93 CSNK2A1 (0.50) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL28777719 0.84 GPR84 (0.54) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL8529327 0.81 CSNK2A1 (0.55) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL5236426 0.79 GPR84 (0.64) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL12288155 0.78 GPR84 (0.47) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL5495155 0.78 GPR84 (0.47) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL395515 0.78 GPR84 (0.47) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL613747 0.78 CSNK2A1 (0.69) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL5495158 0.76 GPR84 (0.46) CSNK2A1GPR84AHRNR4A2CMA1
SCHEMBL8957501 0.76 GPR84 (0.46) CSNK2A1GPR84AHRNR4A2CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 — — EP disclosed
US-7994196-B2 Indazole compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 — — US disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 — — US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 CSNK2A1 1613/4885GPR84 2795/4885AHR 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback